Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: inexperienced (5), immature (1), adolescent (50), green (179), raw (14)

Press release: Cancer expert welcomes HPV vaccine for boys but warns against limited rollout

Description: A cancer expert has welcomed the introduction of the HPV vaccine for boys but warned not extending it to those over
Url: /AboutTheTrust/Newsandpublications/Latestnews/2019/September/Press-release-Cancer-expert-welcomes-HPV-vaccine-for-boys-but-warns-against-limited-rollout.aspx

Docetaxel (75) Prednisolone (6 cycles)) Ver1

Description: Chemotherapy Protocol PROSTATE DOCETAXEL(75)-PREDNISOLONE (6 cycles) Regimen Prostate-Docetaxel (75)-Prednisolone (6 cycles) Indication First line treatm
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Prostatecancer/Docetaxel-75-Prednisolone-6-cycles-Ver1.pdf

Ibrutinib

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia Regimen Ibrutinib • CLL – Ibrutinib Indication • NICE TA 429 recommends ibrutinib alone within its marketing authorisation as
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Ibrutinib.pdf

Zanubrutinib Ver1

Description: Chemotherapy Protocol LYMPHOMA ZANUBRUTINIB Regimen • Lymphoma - Zanubrutinib Indication Zanubrutinib monotherapy for the treatment of patients with previously treated Waldenstrom’s macroglobulinaemia
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Zanubrutinib.pdf

FoM Research Conference programme - final

Description: Faculty of Medicine Research Conference PROGRAMME Tuesday 14th June 2022 Microsoft Teams TIME EVENT SPEAKER 09.15-09.20 MICROSOFT TEAMS
Url: /Media/Southampton-Clinical-Research/Downloads/FoM-Research-Conference-programme-final.pdf

Letrozole-Palbociclib

Description: Chemotherapy Protocol Breast Cancer Letrozole-Palbociclib Regimen • Breast Cancer – Letrozole-Palbociclib Indication • Palbociclib in combination with an aromatase inhibitor is indicated
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Letrozole-Palbociclib.pdf

Exemestane-Palbociclib

Description: Chemotherapy Protocol Breast Cancer Exemestane-Palbociclib Regimen • Breast Cancer – Exemestane-Palbociclib Indication • Palbociclib in combination with an aromatase inhibitor is indicated
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Exemestane-Palbociclib.pdf

Anastrozole-Palbociclib

Description: Chemotherapy Protocol Breast Cancer Anastrozole-Palbociclib Regimen • Breast Cancer – Anastrozole-Palbociclib Indication • Palbociclib in combination with an aromatase inhibitor is indicated
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Anastrozole-Palbociclib.pdf

Nivolumab-Relatlimab

Description: Chemotherapy Protocol SKIN CANCER Nivolumab in combination with Relatlimab (Opdualag) Regimen • Skin – Nivolumab in in combination with Relatlimab (Opdualag) Indication The
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Nivolumab-Relatlimab-Ver1.pdf

Abemaciclib-Letrozole

Description: Chemotherapy Protocol Breast Cancer Abemaciclib-Letrozole Regimen • Breast Cancer – Abemaciclib-Letrozole Indication • Abemaciclib in combination with an aromatase inhibitor is indicated
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Abemaciclib-Letrozole.pdf

1 to 10 of 24

Previous 1 2 3 Next